期刊文献+

Colon cancer and the immune system:The role of tumor invading T cells 被引量:16

Colon cancer and the immune system: The role of tumor invading T cells
下载PDF
导出
摘要 Colon cancer is still one of the leading causes of cancer death worldwide. Although the host immune system has been shown to react against tumor cells, mainly through tumor infi ltrating lymphocytes and NK cells, tumor cells may utilize different ways to escape anti-tumor immune response. Tumor infi ltration of CD8+ and CD4+ (T-bet+) effector T cells has been attributed to a beneficial outcome, and the enhancement of T cell activation through T cell receptor stimulation and co-stimulatory signals provides promising strategies for immunotherapy of colon cancer. Growing evidence supports a role for the Fas/FasL system in tumor immunology, although the mechanisms and consequences of FasL activation in colon cancer are not completely understood. In animal models, depletion of regulatory T cells (CD4+ CD25+ T cells) can enhance the anti-tumor immune response under certain conditions. Taken together, recent insights in the immune reaction against colon carcinoma have provided new approaches to immunotherapy, although much remains to be learned about the exact mechanisms. Colon cancer is still one of the leading causes of cancer death worldwide. Although the host immune system has been shown to react against tumor cells, mainly through tumor infiltrating lymphocytes and NK cells, tumor cells may utilize different ways to escape anti-tumor immune response. Tumor infiltration of CD8+ and CD4+ (T-bet+) effector T cells has been attributed to a beneficial outcome, and the enhancement of T cell activation through T cell receptor stimulation and co-stimulatory signals provides promising strategies for immunotherapy of colon cancer. Growing evidence supports a role for the Fas/FasL system in tumor immunology, although the mechanisms and consequences of FasL activation in colon cancer are not completely understood. In animal models, depletion of regulatory T cells (CD4+ CD25+ T cells) can enhance the anti-tumor immune response under certain conditions. Taken together, recent insights in the immune reaction against colon carcinoma have provided new approaches to immunotherapy, although much remains to be learned about the exact mechanisms.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第45期7233-7238,共6页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献2

二级参考文献16

  • 1[1]Nagata S,Golstein P.The Fas death factor.Science 1995; 267:1449-1456
  • 2[2]Maher S,Toomey D,Condron C,Bouchier-Hayes D.Activation-induced cell death:the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.Immunol Cell Biol 2002; 80:131-137
  • 3[3]Perabo FG,Kamp S,Schmidt D,Lindner H,Steiner G,Mattes RH,Wirger A,Pegelow K,Albers P,Kohn EC,von Ruecker A,Mueller SC.Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.Br J Cancer 2001; 84:1330-1338
  • 4[4]Trauth BC,Klas C,Peters AM,Matzku S,Moiler P,Falk W,Debatin KM,Krammer PH.Monoclonal antibody-mediated tumor regression by induction of apoptosis.Science 1989; 245:301-305
  • 5[5]Yonehara S,Ishii A,Yonehara M.A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.J Exp Med 1989;169:1747-1756
  • 6[6]Krishnakumar S,Kandalam M,Mohan A,Iyer A,Venkatesan N,Biswas J,Shanmugam MP.Expression of Fas ligand in retinoblastoma.Cancer 2004; 101:1672-1676
  • 7[7]Abrams SI.Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.Front Biosci 2005;10:809-821
  • 8[8]Houston A,Bennett MW,O'Sullivan GC,Shanahan F,O'Connell J.Fas ligand mediates immune privilege and not inflammation in human colon cancer,irrespective of TGFbeta expression.Br J Cancer 2003; 89:1345-1351
  • 9[9]Okada K,Komuta K,Hashimoto S,Matsuzaki S,Kanematsu T,Koji T.Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.Clin Cancer Res2000; 6:3560-3564
  • 10[10]Ohta T,Elnemr A,Kitagawa H,Kayahara M,Takamura H,Fujimura T,Nishimura G,Shimizu K,Yi SQ,Miwa K.Fas ligand expression in human pancreatic cancer.Oncol Rep 2004;12:749-754

共引文献20

同被引文献42

引证文献16

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部